Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 606 participants.
Also called NCT02342444
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 606 participants
- Registry
-
NCT02342444
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT02342444. Randomized; no masking; primary purpose prevention. Start 2014-02 (actual); primary completion 2024-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
- Condition
- Trauma
- Condition
- Surgery
- Condition
- Deep Vein Thrombosis (DVT (deep vein thrombosis))
- Condition
- Thromboembolic Events
- Intervention (Drug)
- Enoxaparin Sodium Injection 30 mg BID
- Intervention (Drug)
- Enoxaparin Sodium Injection 40 mg QD
- Lead sponsor
- Oregon Health and Science University
Record details
- Record id
cardio:ct-nct02342444- Content hash
f851d6e11c499d5ff6adad9396083607c2c873c07f7de9fd3cb112a345af4af6